Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cross

Showing results (471-480 of 595) with videos related to

Pageof 60
Sort By:
BMC Medicine|December 13, 2022
Clinical staging and the differential risks for clinical and functional outcomes in young people presenting for youth mental health careWilliam Capon, Ian B Hickie, Mathew Varidel, et al.
Leukemia|October 4, 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemiaNicholas C P Cross, Thomas Ernst, Susan Branford, et al.
Annals of Hematology|September 28, 2014
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genesJuliana Schwaab, Marcin Knut, Claudia Haferlach, et al.
Leukemia|April 17, 2013
Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patientsD M Ross, M O'Hely, P A Bartley, et al.
British Journal of Haematology|August 1, 2020
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemiaGraeme Smith, Jane Apperley, Dragana Milojkovic, et al.
JMIR Research Protocols|June 14, 2021
Supporting Clinicians to Use Technology to Deliver Highly Personalized and Measurement-Based Mental Health Care to Young People: Protocol for an Evaluation StudyHenriette C Dohnt, Mitchell J Dowling, Tracey A Davenport, et al.
Blood|October 4, 2019
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinibJennifer M O'Sullivan, Angela Hamblin, Christina Yap, et al.
Leukemia|January 23, 2013
JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasmsJ Wang, Z Xu, L Liu, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Nature Communications|January 14, 2015
Experimental evidence for the co-evolution of hominin tool-making teaching and languageT J H Morgan, N T Uomini, L E Rendell, et al.
Pageof 60

Showing results (471-480 of 595) with videos related to

Sort By:
Pageof 60
BMC Medicine|December 13, 2022
Clinical staging and the differential risks for clinical and functional outcomes in young people presenting for youth mental health careWilliam Capon, Ian B Hickie, Mathew Varidel, et al.
Leukemia|October 4, 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemiaNicholas C P Cross, Thomas Ernst, Susan Branford, et al.
Annals of Hematology|September 28, 2014
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genesJuliana Schwaab, Marcin Knut, Claudia Haferlach, et al.
Leukemia|April 17, 2013
Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patientsD M Ross, M O'Hely, P A Bartley, et al.
British Journal of Haematology|August 1, 2020
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemiaGraeme Smith, Jane Apperley, Dragana Milojkovic, et al.
JMIR Research Protocols|June 14, 2021
Supporting Clinicians to Use Technology to Deliver Highly Personalized and Measurement-Based Mental Health Care to Young People: Protocol for an Evaluation StudyHenriette C Dohnt, Mitchell J Dowling, Tracey A Davenport, et al.
Blood|October 4, 2019
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinibJennifer M O'Sullivan, Angela Hamblin, Christina Yap, et al.
Leukemia|January 23, 2013
JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasmsJ Wang, Z Xu, L Liu, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Nature Communications|January 14, 2015
Experimental evidence for the co-evolution of hominin tool-making teaching and languageT J H Morgan, N T Uomini, L E Rendell, et al.
Pageof 60